Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
top of page
Companies in the News
Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...
- Dec 4, 2021
Landus and Indigo Join Forces to Elevate Farmers’ Profitable Role in Digital Ag Landscape
Landus farmers will gain access to new carbon revenue stream and digital grain marketing tools AMES, Iowa (December 2, 2021) – Landus,...
- Nov 19, 2021
Generate Biomedicines Announces Raise of $370 Million to Advance its Drug Generation Platform
Cambridge, Mass, November 18, 2021 – Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent...
- Nov 4, 2021
Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation
Tessera’s Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their...
- Oct 20, 2021
Laronde banks $440M to ramp up RNA-based meds that could turn cells into protein factories
Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years....
- Oct 7, 2021
Neumora Therapeutics Launches to Pioneer a New Era of Precision Medicines for Brain Diseases
Redefining neuroscience research and development with a data-driven precision neuroscience platform to develop targeted therapies for...
- Aug 25, 2021
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company
Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW SAN DIEGO,...
- Aug 5, 2021
BiotechBayer bets $1.5B that Vividion will help it target the 'undruggable' and make 1+1=3
Sometimes, it takes $1.5 billion to make "one plus one equal three." Bayer wanted to "really transform" its R&D engine under its recently...
- Jul 28, 2021
Ring Therapeutics Raises $117 Million in Series B Funding to Expand Novel Vector Platform
Ring's novel vector Anellogy™ platform harnesses unique properties of anelloviruses to create a pipeline of redosable vectors compatible...
bottom of page